Onychomycosis Treatment Guidelines

Introduction to Onychomycosis Treatment

The British Association of Dermatologists explicitly states there are no published studies on the efficacy of salicylic acid in fungal nail infection and its use cannot be recommended 1, 2, 3
While salicylic acid has keratolytic properties that could theoretically help with penetration, there is insufficient evidence to support its use as monotherapy for onychomycosis 4
Salicylic acid is mentioned as a component in some topical preparations with antifungal, antiseptic and keratolytic properties, but lacks specific evidence for efficacy in nail fungal infections 1, 3

Oral therapy is strongly preferred over topical treatments for most cases of onychomycosis, according to the British Association of Dermatologists 1, 3, 5
Terbinafine is the first-line oral treatment with the highest recommendation (strength A, evidence level 1+) for dermatophyte onychomycosis, as recommended by the British Association of Dermatologists 4, 6
Itraconazole is an alternative first-line treatment, particularly effective for Candida infections, as recommended by the British Association of Dermatologists 4, 6

Topical therapy should only be used in superficial white onychomycosis (SWO), very early distal lateral subungual onychomycosis (DLSO), or when systemic therapy is contraindicated, according to the British Association of Dermatologists 1, 3
Amorolfine 5% nail lacquer has shown approximately 50% effectiveness in distal nail infections, as reported by the British Association of Dermatologists 1, 3, 6
Ciclopirox 8% nail lacquer has demonstrated mycological cure rates of 34% versus 10% with placebo, as reported by the British Association of Dermatologists 6
Tioconazole 28% solution has shown variable results with cure rates ranging from 20-70%, according to the British Association of Dermatologists 1, 3, 4

Confirm diagnosis with mycological examination (direct microscopy and culture) before initiating treatment, as recommended by the British Association of Dermatologists 7
Assess infection severity and type: If superficial white onychomycosis or very early distal infection, consider topical therapy; for all other presentations, oral therapy is preferred, according to the British Association of Dermatologists 1, 3
Select appropriate treatment: For dermatophyte infections, Terbinafine (first choice) or itraconazole; for Candida infections, itraconazole is preferred; when oral therapy is contraindicated, use amorolfine or ciclopirox nail lacquer, as recommended by the British Association of Dermatologists 4, 6, 7

The most common cause of treatment failure is incorrect diagnosis made on clinical grounds alone without mycological confirmation, as reported by the British Association of Dermatologists 5
Treatment failure rates of 20-30% are common even with the most effective agents, according to the British Association of Dermatologists 7
Onychomycosis has high recurrence rates (40-70%), requiring preventive strategies, as reported by the British Association of Dermatologists 6

For fungal nail infections of fingers and toes, oral terbinafine 250 mg once daily is the first-line treatment: 6 weeks for fingernails and 12 weeks for toenails, as recommended by the British Journal of Dermatology 8

For Limited Disease, superficial white onychomycosis only, very early distal infection with <80% nail plate involvement and no lunula involvement, or when oral therapy is contraindicated, topical therapy may be considered, according to the British Journal of Dermatology 9
For Most Other Cases, any infection beyond the criteria above, oral therapy with terbinafine 250 mg daily is recommended: 6 weeks for fingernails, 12 weeks for toenails, with a high level of evidence (strength A, level 1+), as stated by the British Journal of Dermatology 8

For Diabetic Patients, terbinafine is strongly preferred over itraconazole due to low risk of drug interactions and hypoglycemia, as recommended by the British Journal of Dermatology 8
For Immunosuppressed Patients, terbinafine or fluconazole are preferred over itraconazole due to reduced drug interactions with antiretrovirals and immunosuppressants, according to the British Journal of Dermatology 8
For Pediatric Patients, pulse itraconazole or terbinafine daily may be used, with pediatric cure rates being higher than adults (88-100% in studies), as reported by the British Journal of Dermatology 8

Underdosing or insufficient treatment duration leads to poor outcomes, as stated by the British Journal of Dermatology 8
Using topical therapy for extensive disease results in predictable failure, according to the British Journal of Dermatology 9
Not considering drug interactions in patients on multiple medications, particularly with itraconazole, is a common pitfall, as warned by the British Journal of Dermatology 8